These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36273104)

  • 1. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.
    Garcia-Gisbert N; Arenillas L; Roman-Bravo D; Rodriguez-Sevilla JJ; Fernández-Rodríguez C; Garcia-Avila S; Velez P; Gibert J; Fernández-Ibarrondo L; Salar A; Florensa L; Bellosillo B; Ferrer A; Calvo X
    Leukemia; 2022 Dec; 36(12):2922-2926. PubMed ID: 36273104
    [No Abstract]   [Full Text] [Related]  

  • 2. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
    Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Batta K; Bossenbroek HM; Pemmaraju N; Wilks DP; Chasty R; Dennis M; Milne P; Collin M; Beird HC; Taylor J; Patnaik MM; Cargo CA; Somervaille TCP; Wiseman DH
    Leukemia; 2021 Nov; 35(11):3299-3303. PubMed ID: 33833384
    [No Abstract]   [Full Text] [Related]  

  • 6. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
    Kar SA; Jankowska A; Makishima H; Visconte V; Jerez A; Sugimoto Y; Muramatsu H; Traina F; Afable M; Guinta K; Tiu RV; Przychodzen B; Sakaguchi H; Kojima S; Sekeres MA; List AF; McDevitt MA; Maciejewski JP
    Haematologica; 2013 Jan; 98(1):107-13. PubMed ID: 22773603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Aortic Thromboembolism Associated With
    Bukhari S; Saati A; Abuhalimeh B; Ouma G
    J Investig Med High Impact Case Rep; 2024; 12():23247096231224366. PubMed ID: 38214069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
    Gurney M; Greipp PT; Gliem T; Knudson R; Al-Kali A; Gangat N; Lasho T; Mangaonkar AA; Finke CM; Patnaik MM
    Leuk Res; 2023 Nov; 134():107391. PubMed ID: 37769597
    [No Abstract]   [Full Text] [Related]  

  • 10.
    Quang VT; Podvin B; Desterke C; Tarfi S; Barathon Q; Badaoui B; Freynet N; Parinet V; Leclerc M; Maury S; Solary E; Selimoglu-Buet D; Duployez N; Wagner-Ballon O; Sloma I
    Haematologica; 2023 Nov; 108(11):3135-3141. PubMed ID: 37102610
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
    Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
    Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
    Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
    PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Csizmar CM; Gurney M; Kanagal-Shamanna R; Chien K; Hammond D; Lasho TL; Finke CM; Dean C; Natu A; Mangaonkar AA; Al-Kali A; Gangat N; Tefferi A; Alkhateeb H; Garcia-Manero G; Komrokji RS; Ali NA; Padron E; Montalban-Bravo G; Patnaik MM
    Haematologica; 2024 Oct; 109(10):3419-3425. PubMed ID: 38899337
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
    Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
    Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia.
    Walsh C; Hunter A; Lasho T; Finke C; Ketterling R; Komrokji R; Tefferi A; Mangaonkar A; Howard M; Gangat N; Al-Kali A; Ali NA; Padron E; Patnaik MM
    Leukemia; 2022 Jun; 36(6):1693-1696. PubMed ID: 35351982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.